Latest filing published 10 May 2019 for Travere Therapeutics, Inc..
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +41.1%Entry US$3.09 · Close at T+365 US$4.36
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Timothy P. Coughlin: trading record in brief
Filings by Timothy P. Coughlin span 3 companies, the busiest being Neurocrine Biosciences Inc, Travere Therapeutics, Inc. and Fate Therapeutics Inc. We count 62 filings; the first trade dates from 12 February 2008 and the latest from 8 May 2019.
Market trades split into 1 purchase (€141k) and 46 sales (€10.7M). Taken together, the sales exceed the purchases by €10.6M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 5 share grants and 10 option exercises.
The latest filing, published on 10 May 2019, reports a share grant in Travere Therapeutics, Inc. The most recent open-market purchase was published on 28 November 2016, 3,632 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Timothy P. Coughlin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,000 shares0Common StockSEC:0001209191-19-029153:0
- 2,500 shares0Common StockSEC:0001209191-18-029723:0
- 2,500 shares0Common StockSEC:0001209191-17-033720:0
- 963 shares@ US$43.148.9% of flowCommon StockSEC:0001209191-17-008909:0
- 1,500 shares@ US$42.5513.6% of flowCommon StockSEC:0001209191-17-008136:0
- 1,750 shares@ US$40.6515.4% of flowCommon StockSEC:0001209191-17-004305:0
- 1,750 shares@ US$43.3716.5% of flowCommon StockSEC:0001209191-17-003584:0
- 56,390 shares@ US$2.66100.0% of flowCommon StockSEC:0001209191-16-152153:0Canonical exit: 21 Feb 2017 (T+90)
- 2,000 shares0Common StockSEC:0001209191-16-121504:0
- 1,500 shares@ US$38.0626.4% of flowCommon StockSEC:0001209191-16-095848:0
- 1,750 shares@ US$46.6937.9% of flowCommon StockSEC:0001209191-16-092884:0
- 1,750 shares@ US$44.2535.7% of flowCommon StockSEC:0001209191-16-091250:0
- 20,000 shares@ US$5.76Common StockSEC:0001209191-15-061949:0
- 20,000 shares@ US$55.00Common StockSEC:0001209191-15-061949:1
- 20,000 shares@ US$5.76Common StockSEC:0001209191-15-060833:0
- 20,000 shares@ US$50.00Common StockSEC:0001209191-15-060833:1
- 18,938 shares@ US$2.59Common StockSEC:0001209191-15-051964:0
- 41,062 shares@ US$2.59Common StockSEC:0001209191-15-051964:1
- 60,000 shares@ US$45.08Common StockSEC:0001209191-15-051964:2
- 20,000 shares0Common StockSEC:0001209191-15-031981:0
- 40,000 shares@ US$2.59Common StockSEC:0001209191-15-028992:0
- 40,000 shares@ US$44.49Common StockSEC:0001209191-15-028992:1
- 1,750 shares@ US$30.81Common StockSEC:0000914475-15-000049:0
- 1,750 shares@ US$28.37Common StockSEC:0000914475-15-000033:0
- 10,000 shares@ US$27.25Common StockSEC:0000914475-15-000016:1
25 of 56 declarations
